Filing Flows › Health Care › Biotricity (BTCY)
Biotricity (BTCY) earnings and revenue breakdown
Latest: Q1 FY27 · 10-Q filed Aug 19, 2026 · Biotricity (BTCY) Q1 FY27 earnings results →
Q1 FY27 Revenue up 10% year over year to $4.3M · 22¢ of every $1 of revenue lost · operating margin 3.7%
Biotricity made $4.3M in Q1 FY27 (+10% Y/Y): Technology Fees $4.2M, Device Sales $111K. Operating margin 3.7%, net loss $959K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 19, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4.3M in Q1 FY27, up 10% year over year and up 1% from the previous quarter. Technology Fees was the largest line at 97% of revenue. Technology Fees added $795K year over year (up 24%), 197% of the total change. Device Sales declined 78%.
Gross margin was 82.6%, up 2.1 points from Q1 FY26. Operating profit was $158K, a 3.7% margin (down 3.6 points year over year). Operating profit fell $124K even though revenue rose $403K versus Q1 FY26, so costs grew faster than sales. Operating expenses grew 19% against revenue growth of 10%. The fastest-growing cost line was SG&A (+26%). The quarter ended with a net loss of $1.0M, wider than the previous quarter's $324K loss. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was $507K. Non-cash charges added back $1K of depreciation and $340K of share-based compensation. Working capital and other items added $1.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 FY27 | 10-Q | Aug 19, 2026 | $4.3M | +10% | 3.7% | −$959K | $507K |
| Q4 FY26 | 10-K | Jul 14, 2026 | $4.3M | +15% | 16.3% | −$324K | −$21K |
| Q3 FY26 | 10-Q | Feb 11, 2026 | $4.0M | +10% | 11.1% | −$717K | −$740K |
| Q2 FY26 | 10-Q | Nov 14, 2025 | $3.9M | +19% | 7.0% | −$691K | $416K |
| Q1 FY26 | 10-Q | Aug 14, 2025 | $3.9M | +21% | 7.3% | −$672K | −$373K |
| Q4 FY25 | 10-K | Jul 15, 2025 | $3.7M | +16% | -23.1% | −$1.9M | −$401K |
| Q3 FY25 | 10-Q | Feb 19, 2025 | $3.6M | +22% | -4.7% | −$1.2M | −$88K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Biotricity
Biotricity Inc. (the “Company”, “Biotricity”, “we”, “us”, “our”) is a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established. We believe this approach reduces the risk associated with traditional medical device development and accelerates the path to revenue. In post-diagnostic markets, we intend to apply medical grade biometrics to enable consumers to self-manage, thereby driving patient compliance and reducing healthcare costs.
In its own words, from its 10-K, filed Jul 14, 2026.
Biotricity against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +5%. Operating margin: 3.7% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BTCY Biotricity | Q1 FY27 | $4.3M | +10% | 3.7% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Biotricity 10-Q on SEC EDGAR · CIK 1630113 · Surgical & Medical Instruments & Apparatus
More on BTCY
History
Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results